CMPX — Compass Therapeutics. Cashflow Statement
0.000.00%
- $261.35m
- $134.63m
- $0.85m
Annual cashflow statement for Compass Therapeutics., fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -29.5 | -82.2 | -39.2 | -42.5 | -49.4 |
Depreciation | |||||
Non-Cash Items | 4.94 | 55.7 | 5.58 | 4.08 | 8.07 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -4.65 | 6.25 | -1.26 | -2.91 | -4.14 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -26.8 | -19.7 | -34.1 | -40.6 | -44.9 |
Capital Expenditures | -0.106 | -1.89 | -0.212 | -0.03 | -0.044 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0.144 | 0.116 | -151 | 27 | 46.8 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 0.038 | -1.77 | -151 | 27 | 46.8 |
Financing Cash Flow Items | -6.32 | -0.281 | -0.495 | -0.253 | -0.775 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 48.5 | 119 | 75.8 | 2.94 | 17.3 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 21.8 | 97.2 | -110 | -10.7 | 19.3 |